Amphista Therapeutics presents new preclinical data showing the potential of its BRD9 Targeted Glue, AMX-883, to transform the treatment paradigm for acute myeloid leukaemia
Amphista Therapeutics presents new preclinical data showing the potential of its BRD9…
